ReviewDiscover oncology2025
Cellular and molecular mechanisms of arenobufagin in cancer therapy: a systematic review.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in PCL, PLA, and PLGA-Based Technologies for Anticancer Drug Delivery.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for effective and safe therapeutic options is the goal of clinical treatment for cancer patients. In recent years, natural products have received increasing attention in order to develop new drugs with good antitumor effects and fewer side effects. Arenobufagin (ARBU), an important active ingredient extracted from Toad venom, has been shown to exhibit anti-cancer effects in basic research. Studies have revealed that ARBU has a wide range of potent biological activities and plays an important role as an anti-tumor, anti-inflammatory, anti-oxidant, anti-viral, and for the treatment of cardiac insufficiency. ARBU has shown promising anti-cancer activity in preclinical research. Therefore, it has attracted increasing attention from researchers. In this paper, its antitumor effects were reviewed in terms of cell cycle arrest, induction of cell apoptosis and autophagy, improvement of immunity, inhibition of proliferation, angiogenesis, invasion and metastasis. In addition, the safety and toxicity of the compound were further discussed. Follow-up experiments, especially clinical trials, are needed in order to elucidate the benefits and adverse effects of ARBU on cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.